SMid Cap Biotech Analyst Rama, along with CEO Bender of DAWN, assess the market potential of Tovorafenib in pLGG on an Analyst/Industry conference call to be held on April 10 at 10:30 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DAWN:
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Day One Biopharmaceuticals price target lowered to $44 from $48 at Needham
- Oppenheimer still not a buyer of Day One Biopharmaceuticals despite selloff
- Day One not changing endpoint for FIREFLY-1 trial, says JonesResearch
- Day One FIREFLY-2 update brings two possible issues, says Oppenheimer